Abstract
Tumors treated with preoperative chemotherapy or radiation often demonstrate evidence of response in the resection specimen. Pathologic response is often interpreted as a surrogate for recurrence or survival outcomes. With a valid surrogate for long-term outcomes, investigators can explore treatment strategies with immediate endpoints. The financial and time costs of trials measuring recurrence and survival may be lessened by using short-term pathologic outcomes as an endpoint. This review is intended to examine the current status of pathologic response as a surrogate for tumor behavior. We address questions regarding the definitions of pathologic response, as well as the current literature regarding the meaning of pathologic response for some common tumor types. We explore some of the potential confounding effects that may explain the frequent discordance between tumor response and patient outcomes. In addition, we address some alternative strategies to gauge the response of a tumor to preoperative therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.